IL-PRICEFX
Pricefx , the global leader in cloud-native pricing software, today announced it has received $65 million in Series C funding, bringing the company’s total raised to date to $130 million. The round was led by funds advised by Apax Digital , the growth equity team of Apax Partners, with participation from existing investor Digital+ Partners . Pricefx will use the new funding to expand and solidify its global market leadership position as the only true SaaS platform in the pricing industry, accelerate product innovation, extend its partner ecosystem, and evaluate strategic acquisitions.
SaaS solutions have faced increased demand since pandemic measures forced companies to rapidly and radically address digital transformation initiatives. Pricing software, in particular, has seen a tremendous surge in interest owing to the strong return on investment, even in downturns. As a result, Pricefx has signed more than a dozen new customer deals since March of this year.
“Pricing is being recognized as a critical competency for global enterprises and Pricefx is leading the way for a SaaS-based approach,” said Marcin Cichon, CEO and co-founder of Pricefx. “This investment from Apax confirms Pricefx’s resilience, ability to grow its customer base, and innovate – even during challenging times. This investment will further power our global commercial strategy and aggressive product innovation, by attracting critical talent, expanding our growing ecosystem of partners, and enabling further potential strategic acquisitions – all in pursuit of our mission to bring pricing solutions to as many companies as we can, as simply and effectively as possible.”
Pricefx provides a suite of cloud-based pricing software tools – from Price Optimization, Management (PO&M) to Configure-Price-Quote (CPQ) – for B2B and B2C enterprises of all sizes. Additionally, the company launched the first “6 weeks to live” activation accelerator with Lightning , delivering industry-leading time-to-value. The company has supported its clients through the COVID-19 crisis with initiatives such as providing access to its Sales Insights solution free of charge. In May, Pricefx acquired French market leader Brennus Analytics , which brought industry-leading AI capabilities in pricing optimization and Pricefx’s Optimized Dynamic Pricing solution was recently named an SAP endorsed app .
“Pricing is one of the most important value creation levers for businesses, and we share Pricefx’s passion for making pricing software easier, faster and more accessible,” said Mark Beith, Partner of Apax Digital. “Companies are abandoning inefficient manual processes, disparate spreadsheets, and sub-optimal prices, and embracing Pricefx’s next-gen software, which dynamically manages, optimizes and updates prices across all channels.”
“We are thrilled to join Marcin and the whole Pricefx family on their mission to democratize pricing software and deliver best-in-class time to value and exceptional return on investment to their customers,” said Daniel O’Keefe, Managing Partner of Apax Digital.
Concurrent with this investment, Beith and O’Keefe will join Pricefx’s supervisory board.
“We are excited and proud to continue supporting the Pricefx team on their global growth journey. Pricefx demonstrates a relentless drive towards product innovation and customer success and we believe that they are well on-track to build the undisputed global category leader in pricing software,” said Axel Krieger, Founding Partner at Digital+ Partners.
Pricefx was recently named a finalist in Ventana’s 13th Annual Digital Innovation Awards . These awards identify the top technologies that have the most striking impact in their respective markets, recognizing pioneering vendors that contribute advancements in technology, drive change and increase value for organizations worldwide. The company has several disruptive innovations coming this year, including a self-service version of its analytics software, industry-specific Accelerator packages, enhanced CPQ functionality, and an AI-enhanced upgraded version of its PriceOptimizer product.
About Apax Digital
The Apax Digital Fund specializes in growth equity and buyout investments in high-growth enterprise software, consumer internet, and technology-enabled services companies worldwide. The Apax Digital team leverages Apax Partners’ deep tech investing expertise, global platform, and specialized operating experts, to enable technology companies and their management teams to accelerate the achievement of their full potential. For further information, please visit: www.apax.com/digital .
Over its more than 40-year history, Apax Partners has raised and advised funds with aggregate commitments of c.$50 billion. These funds provide long-term equity financing to build and strengthen world-class companies. For more information see: www.apax.com .
About Digital+ Partners
Digital+ Partners is a leading technology growth equity investor focused on European and US technology companies with €350 million assets under management. Digital+ aims to support ambitious entrepreneurs build global technology leaders, providing them with strategic advice and long-term financial support to help them define and execute their growth plans. The fund focuses exclusively on B2B technology investments and leverages a deep corporate network to help portfolio companies access new markets and build new partnerships. For more information please visit: www.dplus.partners .
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Its innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Pricefx delivers Passion for Pricing. For more information, please visit www.pricefx.com .
###
Notes to Editors:
London-headquartered Apax Partners (www.apax.com ) and Paris-headquartered Apax Partners (www.apax.fr ) had a shared history but are separate, independent private equity firms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005024/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom